With respiratory illness season at its peak, the latest CDC data shows a significant rise in flu cases nationwide, while COVID-19 cases decline and RSV activity continues to wane. According to the CDC ...

Flu, RSV and other respiratory illnesses are sending people to urgent care and emergency rooms. In some cases, these patients are ending up with pneumonia. Flu, RSV and other respiratory illnesses are ...

An average of 961 hospital beds were filled each day last week by patients with diarrhoea and vomiting or norovirus-like symptoms, up 7% from 898 the previous week, which had been the highest so ...

There have been calls for caution when it comes to the use of Pfizer’s respiratory syncytial virus (RSV ... “Until clearer information comes out about the potential confounding effects ...

there is some COVID-19 and respiratory syncytial virus infections mixed in, as well, Baker said. At Trident Health System, "we’re experiencing a higher than average incidence of patients with ...

In line with these findings, increased wall stiffening in patients with CoA and prolonged exposure to abnormal haemodynamics was recently suggested.20 However, despite early surgical repair, the ...

Sales of both GSK’s and Pfizer’s vaccines for respiratory syncytial virus dropped significantly in the last three months of 2024, compared the same period one year before. In a earnings report ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both companies ...

Spanish renewables company X-Elio has signed a 10-year Power Purchase Agreement (PPA) to supply 245GWh of clean energy annually to a cohort of four pharmaceutical companies. The cohort, which includes ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...

Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered in the fourth quarter. The product's sales fell 62% year over year to $198 ...